Synthetic Cannabinoids | CED Foundation

A systematic review of Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia

June 28, 2019 Aging, Alzheimer's Disease, Cannabis, Cannabis Science, Cognition, Dementia, Dronabinol, Memory, Mental Health, Science, Synthetic Cannabinoids, THC

A 2019 literature review summarizes the finding on using THC and CBD on patients with dementia. Researchers found that Dronabinol and THC were associated with significant improvements in a range of psychiatric scores. Interestingly, cannabis products showed the most promising results in patients whose symptoms were previously unmanageable or resistant to other treatments.

View this review (yellow link) or download:

Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia- a systematic review Download

This paper is also stored here: http://bit.ly/2IWFA8R inside the CED Foundation Archive

To explore related information, click the keywords below:

Cannabinoids + opioid pain relief: subjective effects in healthy humans

June 25, 2019 Anti-inflammatory properties, Arthritis, Cannabinoids, Cannabis Science, Case Study, Dronabinol, Muscle Pain, Neuropathy, Opiates, Pain, Science, Synthetic Cannabinoids, THC

Human study finds that, when taken with opioids, dronabinol (THC) may increase impairment and decrease, or not affect, pain relief. Researchers conclude that THC might NOT protect the body from the adverse effects of opioids. However, the study examined only 10 participants, and such a small sample size should give pause to the validity and applicability of the findings.

View this review (yellow link) or download:

Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans Download

This paper is also stored here: http://bit.ly/2IHJuSO inside the CED Foundation Archive

To explore related information, click the keywords below:

THC Has Potential for Treating Agitation in Alzheimer’s Disease

June 24, 2019 Aging, Agitation, Alzheimer's Disease, Anxiety, Behavior change, Cannabinoids, Cannabis, Cannabis Education, Cannabis Science, Case Study, Cognition, Elderly, Future Medicine, Insomnia, Memory, Nabilone, Stigma, Synthetic Cannabinoids

In a crossover trial of 39 patients with Alzheimer’s disease, treatment with nabilone (a synthetic THC analog) was associated with significant improvement in agitation and, remarkably, cognition. Further studies should examine the effects of both THC and CBD in patients with Alzheimer’s disease because anxiety is common in dementia and may exacerbate agitation.

View this review (yellow link) or download:

Tetrahydrocannabinol Has Potential for Treating Agitation in Alzheimer’s Disease Download

This paper is also stored here: http://bit.ly/2IH2BfX inside the CED Foundation Archive

To explore related information, click the keywords below:

Dronabinol: antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns

June 19, 2019 Cancer, Cannabis, Cannabis Science, Dronabinol, Future Medicine, Science, Synthetic Cannabinoids, THC

Study provides rigorous data to support clinical evaluation of THC as a low-toxic therapy option in acute leukemia patients. In related work, full-spectrum, natural derivatives of cannabis may work more effectively than their pharmaceutical counterparts.

View this review (yellow link) or download:

Dronabinol Has Preferential Antileukemic Activity in Acute Lymphoblastic and Myeloid Leukemia With Lymphoid Differentiation Patterns Download

This paper is also stored here: http://bit.ly/2KVVXnD inside the CED Foundation Archive

To explore related information, click the keywords below:

Synthetic Cannabinoids Provide Evidence for Targeting Cannabinoid Receptors in the Treatment of Autoimmune Diseases

June 10, 2019 Anti-inflammatory properties, Arthritis, Autoimmunity, Cannabinoids, Cannabis Science, CB1, CB2, Future Medicine, Muscle Pain, Neuropathy, Science, Synthetic Cannabinoids

Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses

A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.

View this review (yellow link) or download:

Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists Download

This paper is also stored here: http://bit.ly/2HZ6cWb inside the CED Foundation Archive

To explore related information, click keywords:

Producing the ‘problem’ of new psychoactive substances (NPS) in English prisons

June 7, 2019 Adverse Effects, Cannabis, Cannabis News, Law, Legislation, Prisons, Regulation, Social Equity, Synthetic Cannabinoids, UK

The use of synthetic cannabinoids in English prisons is currently considered a “law, order and control” problem, with associated regulation and penalties. There is a clear and problematic disconnect between prison administrators and users. Resources for education, training and work opportunities are missing.

For the full review:

Producing the ‘problem’ of new psychoactive substances (NPS) in English prisons Download